Galectin Therapeutics (GALT) Change in Accured Expenses (2010 - 2026)

Galectin Therapeutics' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$662000.0 for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 26.82% year-over-year to -$662000.0; the TTM figure through Mar 2026 stood at $6.1 million (up 98.21% YoY), while the FY2025 annual figure was $6.2 million, up 40.43% from the prior year.
• Change in Accured Expenses was -$662000.0 for Q1 2026 at Galectin Therapeutics, down from $1.8 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $7.7 million in Q3 2025 to a low of -$3.3 million in Q2 2023.
• Historically, Change in Accured Expenses has averaged $749000.0 across 5 years, with a median of $175000.0 in 2022.
• The sharpest annual moves came in 2023 and 2025: Change in Accured Expenses plunged 267.15% in 2023, then jumped 4561.27% in 2025.
• A 5-year view of Change in Accured Expenses shows it stood at $175000.0 in 2022, then jumped by 276.0% to $658000.0 in 2023, then soared by 810.79% to $6.0 million in 2024, then tumbled by 70.7% to $1.8 million in 2025, then tumbled by 137.7% to -$662000.0 in 2026.
• The last three Change in Accured Expenses figures came in at -$662000.0 (Q1 2026), $1.8 million (Q4 2025), and $7.7 million (Q3 2025), per Business Quant data.